Ideaya Biosciences, Inc.'s stock faces pressure from macroeconomic shifts and FDA policies, but remains a buy for savvy ...

The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical Na ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...

MGNX earnings call for the period ending December 31, 2024. MacroGenics ( MGNX -14.87%) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an ...

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025AVA6103 IND-enabling studies underway with a Phase 1 trial ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed promising efficacy in patients with advanced or metastatic endometrial cancer, ...

In June 2024, Jiangsu Alphamab entered into a research and collaboration agreement with ArriVent BioPharma, Inc. to use Jiangsu Alphamab's proprietary linker-payload (Alphatecan) and glycan-specific ...

MacroGenics, Inc.’s MGNX share price has dipped by 14.19%, which has investors questioning if this is right time to buy.

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...